Therefore, a patient with a presumed diagnosis of XLH presenting with hypercalciuria should never be started on conventional treatment (phosphate supplements and active vitamin D) or burosumab—an FGF23 antibody—as this may promote progressive nephrocalcinosis. This evidence concerns the gene FGF23 and X-linked hypophosphatemia.